- Home
- HSCS
as 11-22-2024 4:00pm EST
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SOUTHLAKE |
| Market Cap: | 2.7M | IPO Year: | 2022 |
| Target Price: | $15.00 | AVG Volume (30 days): | 26.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -13.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.36 - $29.00 | Next Earning Date: | 12-12-2024 |
| Revenue: | $18,600 | Revenue Growth: | 853.85% |
| Revenue Growth (this year): | 8948.39% | Revenue Growth (next year): | 27.27% |
Latest Heart Test Laboratories Inc. News
HSCS Breaking Stock News: Dive into HSCS Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement
GlobeNewswire
a month ago
HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit
GlobeNewswire
2 months ago
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
MT Newswires
2 months ago
Heart Test Laboratories Closes Non-Dilutive Financing; Shares Rise
GlobeNewswire
2 months ago
HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
GlobeNewswire
4 months ago
HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
GlobeNewswire
4 months ago
Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency
GlobeNewswire
4 months ago
HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare
Compare HSCS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HSCS Heart Test Laboratories Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.